| |
|
|
|
Adamas Pharma  
|
|
5.08 0.36 (0.08%) |
01-25 16:00 |
|
Open: |
5 |
Pre close: |
4.72 |
Target:
|
6.19 
|
|
High: |
5.24 |
Low: |
4.81 |
Resistance:
|
5.30
6.19
|
|
Volume: |
717,632 |
Market Cap: |
145M |
Support:
|
4.56
4.11
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
4.68
|
MACD |
MACD(12,26):
|
0.04 |
|
MA(20): |
4.56 |
Signal(12,26,9): |
0.01 |
|
MA(100): |
4.42  |
Stochastic Oscillator |
%K(14,3):
|
64.70 |
|
MA(250): |
3.84 |
%D(3): |
56.13 |
|
Average Volume(K) |
3-Month: |
18134
|
52-Week |
High:
|
6.02 |
|
10-Days: |
17902 |
Low: |
1.90 |
|
RSI |
RSI(14):
|
63.52 |
Change(%): |
-4.2 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.212 |
Return on Equity (ttm) |
0.0 |
Shares Out. (M) |
28.52 |
|
EPS Est. Current Year |
-3.770 |
Return on Assets (ttm) |
-18.7 |
Shares Float (M) |
19.20 |
|
EPS Est. Next Year |
-3.420 |
PEG Ratio |
0.00 |
% Held by Insiders |
2.73 |
|
EPS Est. Next Quarter |
-1.170 |
Qtrly Rev. Growth |
44.8 |
% Held by Institutions |
68.33 |
|
Forward EPS |
-3.800 |
Gross Profit (p.s.) |
1.829 |
Shares Short (K) |
1630 |
|
Book Value (p.s.) |
-1.210 |
EBITDA (p.s.) |
-1.610 |
P/E |
-2.30 |
|
Sales Per Share |
2.447 |
Qtrly Earnings Growth |
0.00 |
P/BV |
-4.20 |
|
Profit Margin |
-89.12 |
Operating Cash Flow
(M) |
-58.69 |
P/S |
2.08 |
|
Operating Margin |
-67.12 |
Levered Free Cash Flow
(M) |
-39.61 |
P/CF |
-2.47 |
|
|
|
|
|
|
